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How I treat splenomegaly in myeloﬁbrosis
F Cervantes
Hematology Department, Hospital Clı ´nic, IDIBAPS, University of Barcelona, Barcelona, Spain
Symptomatic splenomegaly, a frequent manifestation of
myeloﬁbrosis (MF), represents a therapeutic challenge. It is
frequently accompanied by constitutional symptoms and by
anemia or other cytopenias, which make treatment difﬁcult, as
the latter are often worsened by most current therapies.
Cytoreductive treatment, usually hydroxyurea, is the ﬁrst-line
therapy, being effective in around 40% of the patients, although
the effect is often short lived. The immunomodulatory drugs,
such as thalidomide or lenalidomide, rarely show a substantial
activity in reducing the splenomegaly. Splenectomy can be
considered in patients refractory to drug treatment, but the
procedure involves substantial morbidity as well as a certain
mortality risk and, therefore, patient selection is important. For
patients not eligible for splenectomy, transient relief of the
symptoms can be obtained with local radiotherapy that, in turn,
can induce severe and long-lasting cytopenias. Allogeneic
hemopoietic stem cell transplantation is the only treatment with
the potential for curing MF but, due to its associated morbidity
and mortality, is usually restricted to a minority of patients with
poor risk features. A new class of drugs, the JAK2 inhibitors,
although also palliative, are promising in the splenomegaly of
MF and will probably change the therapeutic algorithm of this
disease.
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Introduction
Myeloﬁbrosis (MF) is a chronic myeloproliferative neoplasm
(MPN) characterized by bone marrow ﬁbrosis, extramedullary
hemopoiesis with splenomegaly and leukoerythroblastosis in
blood.
1 The disease can appear de novo (primary MF or PMF) or
as evolution of a previously known MPN, either polycythemia
vera (PV) (post-PV MF) or essential thrombocythemia (ET) (post-
ET MF).
2 Irrespective of MF being primary or to follow a
previous MPN, once it is diagnosed, its clinical and histological
characteristics and prognosis are essentially the same. MF is a
clonal proliferation of a pluripotent hemopoietic stem cell,
3,4 in
which the resulting abnormal cell population releases several
cytokines and growth factors in the bone marrow that lead to the
appearance of marrow ﬁbrosis and stroma changes, and
colonizes extramedullary organs such as the spleen and the
liver.
2 The mutation V617F in the JAK2 gene is present in more
than a half of patients with PMF or post-ET MF, and in 95% of
those with post-PV MF.
5–8 Mutations in the MPL gene (the gene
of the thrombopoietin receptor) are observed in 4–8% of
patients with PMF and post-ET MF but not in post-PV MF.
9,10
These molecular ﬁndings have contributed to a better under-
standing of the pathogenesis of MF, but the diagnosis of the
disease remains mainly of exclusion.
MF is an infrequent disease that usually affects elderly
people.
11 Currently, median survival approaches 6 years, but
there is a wide variability, ranging from less than 1 year to more
than 2 decades.
11 A number of prognostic factors have been
identiﬁed and, recently, important progress has been made in
the prognostic stratiﬁcation of MF patients, both at diagnosis
11
and during the disease evolution,
12,13 with four prognostic
groups with markedly different survival having been recognized
(Table 1).
MF is a heterogeneous disease, not only with regard to its
prognosis but also to its clinical and hematologic manifestations.
Around 30% of patients are asymptomatic at diagnosis and
can remain in this fashion for variable periods of time.
11
However, most patients have symptoms already at presentation,
most frequently derived from anemia and splenomegaly, and
constitutional symptoms. To date, allogeneic hemopoietic stem
cell transplantation (allo-HSCT) is the only therapy with
the potential for curing MF
14–16 but, in practice, owing to the
advanced age of most patients, the lack of donor and, especially,
the substantial morbidity and mortality associated with the
procedure, allo-HSCT is restricted to a few patients, usually
included within the intermediate-2 and high-risk prognostic
categories. Therefore, for the majority of patients with MF, the
disease remains incurable, with its therapy being merely
palliative. Because of this, and given the heterogeneity of
the clinical manifestations of the MF, it is important to adjust
the treatment to the characteristics of the disease in each
individual patient.
The splenomegaly of MF
Splenomegaly, one of the most characteristic features of MF, is
due to extramedullary hemopoiesis (also called myeloid
metaplasia),
17 which affects not only the spleen but also the
liver (and, for this reason, hepatomegaly and alterations of the
liver function often coexist) and, more unfrequently, other sites
such as the lung, the kidney, the central nervous system, the
lymph nodes or the skin. The spleen is palpable in up to 90%
of MF patients at presentation.
11 In this sense, it must be noted
that if the spleen is not palpable at diagnosis and does not
become palpable after 1 or 2 years, the possibility of other
conditions such as myelodysplasia, which can also cause
cytopenias and marrow ﬁbrosis, should be excluded by careful
examination of the bone marrow histopathologic features.
18
Symptoms from splenomegaly usually correlate with spleen
size. Thus, some patients with moderate splenomegaly may
not have local symptoms initially. However, as the spleen
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www.nature.com/bcjprogressively increases, it produces mechanical discomfort in
the left part of the abdomen, occasionally episodes of severe
pain in the left upper quadrant irradiating to the shoulder and
due to splenic infarctions, early saciety and diarrhea. These
symptoms are frequently associated with profound cachexia and
fatigue, accentuation of pre-existing cytopenias and, sometimes,
signs of portal hypertension. Of note, despite its clinical
relevance in MF, splenomegaly is not per se a poor prognostic
factor of the disease, as it is usually observed in patients
displaying other well-recognized unfavorable prognostic factors,
such as severe anemia, constitutional symptoms or marked
leukocytosis.
11
Treatment of splenomegaly
It is generally agreed that, if patients with MF have no
symptoms, a wait-and-see approach is a reasonable option,
with treatment being delayed until signiﬁcant changes are
observed.
19 It is likely that such conservative approach will
change as soon as more effective therapies for the disease will
become available. The above wait-and-see policy also applies
to asymptomatic splenomegaly, especially taking into account
that MF patients have often concurrent cytopenias that may
worsen following treatment institution.
Myelosuppressive therapy
For MF patients with marked and symptomatic splenomegaly,
myelosuppressive drugs are considered as the ﬁrst-line therapy,
with hydroxyurea being the drug of choice.
20–22 Although
hydroxyurea has been (and still is) the drug most frequently used
in this setting, information on its efﬁcacy in MF has been based
on a few reports that included a scarce number of patients.
20,21
In this sense, in a recent publication from our group on the
results of hydroxyurea therapy in 40 MF patients with
‘hyperproliferative’ disease,
22 symptomatic splenomegaly was
the reason for treatment initiation in 45% of patients. The
starting dose was 500mg/day and it was subsequently adjusted
to the individual efﬁcacy. In those patients who responded, the
required dose to maintain the response was variable, ranging
from 500mg to 2g daily. According to the International
Working Group for MF Research and Treatment (IWG-MRT)
criteria,
23 response in splenomegaly was 40%, including
disappearance of the palpable splenomegaly in 4 patients and
a 450% reduction in spleen size in 12 patients. Median
duration of the response was 13.2 months, being long lasting in
some patients (range: 3–126.2 months). Coincidently with
hydroxyurea treatment, worsening of the anemia or appearance
of pancytopenia was observed in almost a half of the patients,
requiring administration of erythropoietin-stimulating agents,
which were effective almost exclusively in patients with
inadequate erythropoietin serum levels (o125U/l) and non-
transfusion-dependant anemia, or danazol. Therefore, to avoid
the development or the accentuation of a pre-existing anemia,
I usually start at a dose of 500mg/day, following the patient
every 3–4 weeks during the initial phase of treatment to allow
for dose titration. Once the appropriate dose is found, controls
can be delayed to every 2–3 months, unless the patient requires
red blood cell transfusions. Oral or leg ulcers, the most
characteristic extrahematologic toxicity of hydroxyurea, occa-
sionally develop, usually in association with prolonged admini-
stration and high doses of the drug.
Busulfan, an alkylating drug, can also be used to treat
symptomatic splenomegaly
24 but, due to its prolonged effect
and the risk of provoking long-lasting cytopenias, it requires a
close control of the patients, making it inconvenient in clinical
practice. Busulfan is contraindicated in the presence of
leukocytes o410
9/l or platelets o10010
9/l, as the drug
accumulates in the bone marrow, where it continues exerting its
effect for several weeks. I have treated with busulfan a number
of MF patients resistant or intolerant to hydroxyurea, who were
not eligible for other therapies. In these cases, I usually give a
low dose (2mg/day) and follow the patients closely (every 3–4
weeks) to watch for possible development of leukopenia
(o410
9/l) or thrombocytopenia (o10010
9/l), which man-
date immediate treatment stop. The drug was effective in some
of the patients, with a progressive effect on spleen size being
observed over the months. Once treatment was stopped because
of decreasing hematologic values, some of the patients could
remain untreated for several months, until spleen increase,
accompanied by recovery of the hematologic values, led to
treatment reinstitution.
Low-dose melphalan (2.5mg for 3 days a week) yielded
favorable responses in 66 of 99 patients with hyperproliferative
MF.
25 Splenic size, leukocytosis and thrombocytosis normalized
in 23%, 86% and 93% of patients, respectively. Anemia
improved in 12 of 20 patients not requiring transfusion and 6
of 16 became transfusion independent. However, the leukemo-
genic potential of melphalan probably explains its scarce use in
clinical practice.
In patients with massive, refractory splenomegaly, intrave-
nous courses of cladribrine (2-CdA), a purine nucleoside analog,
given once-monthly for 4–6 months, produced around 50% of
responses that were mostly durable, with a median duration of 6
months after treatment discontinuation.
26 Severe cytopenia was
the main toxicity. It must be noted, however, that use of the
above drug in MF is off-label.
Interferon
Despite in vitro data suggesting that interferon-a (IFN) could
correct bone marrow ﬁbrosis, in practice, the contribution of this
drug to the treatment of MF has been minor, if any, owing to its
limited efﬁcacy and its frequent hematologic and extrahemato-
logic toxicity, which leads to treatment discontinuation in the
majority of patients.
27–29 Recently, promising results have been
reported with the use of the pegylated form of IFN.
30 However,
the mid-term toxicity of pegylated IFN in other diseases is not
Table 1 Current prognostic stratiﬁcation of patients with primary
myeloﬁbrosis
Variable
a IPSS DIPSS DIPSS-plus
Age 465 years + + +
Constitutional symptoms + + +
Hb o10g/dl + + +
Leukocytes 42510
9/l + + +
Circulating blasts 41% + + +
Transfusion need +
Platelet count o10010
9/l +
Unfavorable kayotype
(+8, 7, 7q, 5, 5q, iso 17q,
inv (3), 12p-, 11q23 rearrangement)
+
Abbreviations: DIPSS, dynamic IPSS; IPSS, international prognostic
scoring system.
aEach variable scores 1 point, except 2 points for Hb o10g/dl in the
DIPSS.
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especially considering the advanced age of most MF patients. It
is, therefore, quite unlikely that pegylated IFN could have a
relevant role in the therapy of MF.
Immunomodulatory drugs
The immunomodulatory drugs, which include thalidomide,
lenalidomide and pomalidomide, are a group of drugs that
inhibit several cytokines and have antiangiogenic effects. They
are used in patients with MF, alone or in combination with
prednisone.
31–35 Side effects are frequent, especially in the
case of thalidomide (neurological toxicity) and lenalidomide
(myelosuppression), and the responses are seen mostly in the
anemia, whereas the drugs rarely have a substantial activity
in the splenomegaly. Therefore, I would not recommend this
type of therapy for MF patients with marked, symptomatic
splenomegaly.
Splenectomy
Splenectomy involves a substantial risk in patients with MF.
36–38
In a single-institution series, operative morbidity was 31%
and mortality 9%, usually during the 3-month post-splenectomy
period.
38 Main complications are bleeding (especially hemo-
peritoneum), infections and thrombosis. In addition, massive
hepatomegaly due to compensatory myeloid metaplasia of the
liver develops in 16–24% of patients, some of which die from
liver failure.
39 Post-splenectomy thrombocytosis that increases
the risk of thrombosis, especially in the splenoportal vein tract,
40
is observed in 20% of patients. Following splenectomy, a higher
rate of blast transformation has also been registered in one
study,
41 although this was not conﬁrmed by others.
Splenectomy can be considered in MF patients with heavily
symptomatic splenomegaly refractory to drug treatment, severe
constitutional symptoms, transfusion-dependent anemia (includ-
ing uncontrollable hemolysis) unresponsive to therapy and
portal hypertension secondary to the increased portal ﬂow.
38 As
no survival prolongation from splenectomy has been demon-
strated, the risks of splenectomy should be carefully balanced
against the possible beneﬁts in every individual patient, in order
to restrict the procedure to those patients most likely to beneﬁt
from it. Given the risks associated with the procedure, other
factors such as the patient’s comorbidities and life expectancy
must also be taken into account.
In the series of the Mayo Clinic, durable responses in
constitutional symptoms, transfusion-dependent anemia, portal
hypertension and severe thrombocytopenia were obtained in
67%, 23%, 50% and 0% of cases, respectively.
38 From the
above results, it can be inferred that splenectomy has no role in
the treatment of the thrombocytopenia of MF. Beside, thrombo-
cytosis would be a relative contraindication to splenectomy,
given the high probability of provoking uncontrollable throm-
bocytosis and thrombosis, especially in the splenoportal vein
tract, because of the additional effect of the local injury during
the surgical procedure.
40. Therefore, if platelets are above the
normal range and, despite this, splenectomy is decided, it is
advisable to lower the platelets with hydroxyurea before surgery
to around 20010
9/l and to maintain them at this level in
the post-operative period to reduce the risk of thrombosis.
42
In addition, once it is made sure that peritoneal bleeding has
not occurred within the ﬁrst 24h post surgery, prophylactic
anticoagulation with low-weight molecular heparin should be
instituted and maintained for at least 4–6 weeks.
Peritoneal bleeding, the most life-threatening complication
of splenectomy in these patients, usually occurs during the ﬁrst
24h following surgery. This complication can be related to the
presence of thrombocytopenia but also to the existence of
abnormalities of the platelet function in these patients. Because
of this, I usually transfuse platelet concentrates immediately
after spleen removal in all patients with platelet counts
o15010
9/l. I also do it in patients who actually develop
peritoneal bleeding, in conjunction with the surgical measures
aimed at stopping bleeding. By applying this measure, the
incidence of this complication has dramatically dropped in my
center and no mortality from this origin has been further
observed. However, this personal approach is not supported by
any randomized study.
With regard to the question of splenectomy or no before
allo-HSCT, given the morbidity and mortality of splenectomy
versus the faster hematologic recovery post transplant,
14
splenectomy preceding transplantation is controversial. Although
the current tendency is not to perform splenectomy routinely as
preparation for transplantation,
16 it seems reasonable to carry out
the procedure in patients with massive splenomegaly, taking into
account the higher risk of graft failure in such cases. However,
this scenario will probably change with the availability of the
JAK2 inhibitors, which are highly effective in reducing the
splenomegaly in a high proportion of MF patients.
Radiation therapy
Splenic radiation can be used to reduce the spleen size and
procure symptom relief.
43–45 Total doses range from 0.15 to
65Gy per course, administered in a fractioned form. It can be
indicated in poor candidates to surgery and for palliation of
severe pain from spleen infarct, but its effect is not durable,
whereas the risk of severe and long-lasting cytopenias, with
subsequent infection and bleeding, is high, probably due to
an effect on the circulating progenitors.
43,46 Therefore, routine
use of splenic irradiation in patients with MF should not
be recommended. In this sense, in an attempt to prolong the
therapeutic effect of splenic irradiation while avoiding pancy-
topenia, an induction-maintenance strategy, consisting of
administration of lower radiation doses during induction
followed by maintenance with the same or lower doses, was
recently reported to control not only the splenomegaly but
also the signs of disease acceleration in two MF patients.
47 On
the other hand, splenic radiation to reduce the spleen size in
preparation for splenectomy is not advised, given the higher rate
of post-surgical bleeding observed in such cases,
43 probably
related to the development of splenic adhesions to the
abdominal wall and the surrounding viscera.
JAK2 inhibitors
The discovery of the JAK2 mutation triggered the development
of molecular-targeted therapies for the MPNs, with this
especially applying to MF, given the lack of an appropriate
therapy for many of these patients. However, for the time being,
the expectations that the JAK2 inhibitors could reproduce the
success of the tyrosine kinase inhibitors in chronic myeloid
leukemia have not been substantiated. To date, information on
the use of JAK2 inhibitors in MF is available for four drugs in
clinical development: ruxolitinib (formerly known as
INCB018424), TG101348, CEP-701 and CYT387, whereas
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usually administered to patients with intermediate-2 or high-risk
MF, including PMF and post-PV/ET MF.
Ruxolitinib, an oral JAK1/JAK2 inhibitor, was given to 153 MF
patients in a phase 1/2 trial.
48 Treatment was well tolerated,
with thrombocytopenia as the dose-limiting toxicity. At the dose
of 15mg twice daily, half of the patients had a clinical response,
mainly in the splenomegaly and the constitutional symptoms. In
responding patients, the response is usually dramatic but also
drug- and dose-dependant, as treatment discontinuation or dose
reductions because of side effects are rapidly followed by spleen
increase and reappearance of constitutional symptoms. A small
proportion of patients become transfusion independent and the
same proportion have accentuation of pre-existing anemia. Of
note, the response was independent of the patient’s JAK2
mutational status, whereas no difference was noted between
PMF and post-PV/ET MF. The effect on JAK2V617F allele burden
was limited, and there was no signiﬁcant reduction in the
marrow ﬁbrosis. Normalization of several pro-inﬂammatory
cytokines was noted and this was correlated with symptomatic
improvement, a fact that may be ascribed to the anti-JAK1
activity of the drug. Two different phase 3 multicenter studies
(COMFORT-I and COMFORT-II) have been carried out and their
results have recently been presented.
49,50 The ﬁrst one
49
compared ruxolitinib versus placebo in 309 patients and the
second one
50 ruxolitinib with best-available therapy in 219
patients. Both trials have attained the primary endpoint of
435% reduction in spleen size, as measured by imaging
techniques, at 24 or 48 weeks of treatment start, respectively,
and, based on these results, application for the drug approval is
currently in progress. Ruxolitinib is a good palliative treatment
for a half of MF patients with signiﬁcant splenomegaly. Given its
palliative nature, cost considerations will be important in
deciding if it should be given to all MF patients with signiﬁcant
splenomegaly or if it could be used as a second-line therapy for
patients not responding or losing the response to hydroxyurea.
TG101348 is an inhibitor with preferential activity in JAK2. In
a phase 1/2 study with 59 patients,
51 dose-limiting toxicity was
an increase in the serum amylases, without clinical signs of
pancreatitis. Gastrointestinal adverse events were frequent but
usually moderate and transient. Worsening of anemia, throm-
bocytopenia and neutropenia occurred in 35%, 24% and 10%
of the patients, respectively. At 6 months of treatment, almost
60% achieved a 450% decrease in splenomegaly. The
responses were independent of the JAK2V617F mutational
status, but a 450% decrease in the allele burden was reported
in 40% of mutated patients. Symptomatic response was
achieved in 50–75% and, as opposed to ruxolitinib, improve-
ment in constitutional symptoms did not correlate with changes
in pro-inﬂammatory plasma cytokine levels.
CEP-701 achieved clinical improvement in 6 of 22 MF
patients.
52 However, gastrointestinal toxicity was remarkable,
with diarrhea, nausea and vomiting in 72%, 50%, and 27%,
respectively. No effect on JAK2V617F allele burden or pro-
inﬂammatory cytokines was documented.
In a phase 1/2 study with 108 MF patients,
53 CYT387
produced a response in palpable spleen according to the
IWG-MRT criteria in 45% of cases, whereas resolution of
constitutional symptoms was observed in the majority of
patients. Of note, of the 42 patients evaluable for anemia
response, 50% responded, including 58% of those who were
transfusion dependent. Grade 3–4 thrombocytopenia was
observed in 25% of patients, while hyperlipasemia and head-
ache were the most characteristic non-hematologic side effects.
The above observation of a substantial response rate of the
anemia with CYT387A as compared with other JAK2 inhibitors
can be of clinical interest and warrants conﬁrmation in a larger
number of patients.
Longer follow-up is required to deﬁne the role of the JAK2
inhibitors in the treatment of MF. The trade-offs between clinical
activity and toxicity will be the determinant to choose the
right drug. Beside, information on the possible extra-hematolo-
gic effects in the long term is needed. This having being said,
it is quite likely that the JAK2 inhibitors will have a major role
in the treatment of MF in the coming years, especially for
splenomegaly and constitutional symptoms.
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